Bayer expands research partnership with Chinese university
Will collaborate with Tsinghua University in the area of biomedical sciences over next three years
Bayer HealthCare and Tsinghua University in Beijing, China, are expanding their joint research partnership relating to the Bayer-Tsinghua Joint Research Centre for Innovative Drug Discovery (BTC).
The partners have signed a new strategic agreement to collaborate in the area of biomedical sciences over the next three years.
The BTC was established in 2009 and joint projects start from early research programmes to gain deeper understanding of disease mechanisms and identification of new drug targets, to joint structural biology research and medicinal chemistry programmes.
Bayer HealthCare’s head of global drug discovery, Professor Andreas Busch, said: ‘The decision to further develop this successful research collaboration underlines Bayer’s commitment to China as an important component of our innovation strategy.
Dr Shi Yigong, Professor and Dean of School of Life Sciences, Tsinghua University, added: ‘A new focus of our collaboration will be the area of structural biology, where scientists from Tsinghua University will work in close collaboration with Bayer scientists to solve the 3D protein structure of biological molecular targets as a basis for new drug discovery projects.’
